Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18751713 | 1.00 | MEN1 (0.40) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL18751714 | 1.00 | MEN1 (0.40) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL26382110 | 1.00 | MEN1 (0.40) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL18751712 | 1.00 | MEN1 (0.40) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL18751718 | 1.00 | MEN1 (0.40) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL18751710 | 1.00 | MEN1 (0.40) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL18751715 | 1.00 | MEN1 (0.40) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL13542696 | 0.97 | MEN1 (0.37) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL20661434 | 0.91 | ALDH1A1 (0.38) | MEN1KMT2AHSD17B10BLMPMP22 | |
| SCHEMBL21099966 | 0.91 | MEN1 (0.35) | MEN1KMT2AHSD17B10BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-11780935-B2 | Mutant antibodies and conjugation thereof | PFIZER HEALTHCARE IRELAND (IE) | 2023-10-10 | — | — | US | disclosed |
| US-20230226219-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780935-B2 | Mutant antibodies and conjugation thereof | IGLV6-57, IGSF11, F13B | MEN1 3746/4885KMT2A 1715/4885HSD17B10 3271/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | MEN1 1155/4885KMT2A 927/4885HSD17B10 1409/4885 |
| US-20230226219-A1 | PEG LIPIDOID COMPOUNDS | LIPG, ABCB4, HDLBP | MEN1 4431/4885KMT2A 3605/4885HSD17B10 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.